FDA Approves Rapid Approval For Athersys for Acute Respiratory Syndrome
Athersys, Inc. (Nasdaq: ATHX) declared today that its clinical program assessing MultiStem® cell treatment for the treatment of Acute Respiratory Distress Syndrome (“ARDS”) has gotten Fast Track assignment from the United States Food and Drug Administration (“FDA”). This significant assignment…